Log In
Print this Print this

Pleneva (BGC20-0134)

  Manage Alerts
Collapse Summary General Information
Company BTG plc
DescriptionOral transforming growth factor (TGF) beta 1 (TGFB1) immunomodulator
Molecular Target Transforming growth factor (TGF) beta 1 (TGFB1)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS); Treat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today